Clinical trial
A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee Arthroplasty
NCT07928011 is registered in ClinicalTrials.gov with University of California, Irvine as lead sponsor.
Follow this trial by email Email me the PDF
Summary
Not yet recruiting, started January 2027. Interventional study, Phase 4, 40 participants (estimated). Lead sponsor University of California, Irvine; United States. Primary measures: Participant enrollment; Protocol adherence and 1 more.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Randomized Controlled Trial of Suzetrigine as an Adjunct to Multimodal Analgesia Following Total Knee Arthroplasty
- Lead sponsor
- University of California, Irvine
- Phase
- Phase 4
- Overall status
- Not yet recruiting
- Start date
- January 31, 2027
- Completion date
- April 30, 2027
- Enrollment
- 40 (estimated)
- Sites
- 1
Conditions
As the registry lists them.
total knee arthroplasty
Who could take part, where it ran, who ran it
As filed in ClinicalTrials.gov.
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Healthy volunteers
- No
- Study type
- Interventional
- Sites
- 1
- Countries
- United States
- Lead sponsor
- University of California, Irvine
Arms
As registered; 2 arms.
| Arm | Type | Interventions |
|---|---|---|
| Standard Multimodal Group | No intervention | |
Show registry wordingStandard multimodal control group will receive treatment components such as nerve block through an adductor canal catheter for 4 days, cryotherapy/icing as needed, scheduled non-opioid drug (acetaminophen 1000 mg 3 times a day), nonsteroidal anti-inflammatory drug (NSAID) (Meloxicam 15mg daily), and breakthrough opioid (Oxycodone 5mg every 4 hours as needed). | ||
| Suzetrigine Group | Experimental | Suzetrigine |
Show registry wordingThe Suzetrigine group will receive a 100 mg loading dose of Suzetrigine, followed by 50mg Q12h for 14 days as an addition to a standardized multimodal pain management pathway. The standardized multimodal pain management pathway consists of treatment components such as nerve block through an adductor canal catheter for 4 days, cryotherapy/icing as needed, scheduled non-opioid drug (acetaminophen 1000 mg 3 times a day), nonsteroidal anti-inflammatory drug (NSAID) (Meloxicam 15mg daily), and breakthrough opioid (Oxycodone 5mg every 4 hours as needed). | ||
Primary endpoints
Registered primary outcome measures; 3 primary.
| Measure | Time frame |
|---|---|
| Participant enrollment | At enrollment |
Show registry wordingEnrollment rates | |
| Protocol adherence | Within 14 days |
Show registry wordingProtocol adherence rates | |
| Data collection | At 14 days |
Show registry wordingCompleteness of data collection | |
Patents and exclusivity
By drug, as the FDA Orange Book declares its patents.
-
Suzetrigine
- US 11834441; expires December 4, 2040; assignee Vertex Pharmaceuticals Inc / Ma
Lead sponsor's other trials
University of California, Irvine, most recent start first.
+470 more trials See the organization page